Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
Revenue of Immatics N.V. (IMTX)
Revenue in 2023 (TTM): $54 M
According to Immatics N.V.'s latest financial reports the company's current revenue (TTM) is $54 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Immatics N.V.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $54 M | $-64,666,000 | $-88,929,000 | $-96,994,000 | $-96,994,000 |
| 2022 | $172.83 M | $66.05 M | $50.04 M | $42.04 M | $37.51 M |
| 2021 | $34.76 M | $-52,811,000 | $-83,560,000 | $-93,335,000 | $-95,061,000 |
| 2020 | $31.25 M | $-35,831,999 | $-64,441,000 | $-229,616,000 | $-229,348,000 |
| 2019 | $18.45 M | $-21,642,000 | $-29,155,000 | $-32,487,000 | $-31,741,000 |
| 2018 | $3.77 M | $-30,201,000 | $-31,726,000 | $-32,355,000 | $-31,444,000 |